Comprehensive Oncomine Precision Assay (OPA) Gene Panel (ThermoFisher Scientific)
Australian Clinical Labs offers a Comprehensive Tumour Somatic Mutation Panel including oncogenes and tumour suppressor genes that are frequently mutated in solid tumours aiding clinicians to select the most appropriate treatment for their patients. Please see table below.
When to use
This panel can be helpful in elucidating the genetic profile of multiple gene pathways of a given tumour which is potentially useful in designing tailored treatment regimens that avoid unnecessary toxic therapy, resistance or overtreatment. It is also of valuable use if the tumour is poorly differentiated or of unknown origin. Larger gene panel profiling may actually identify previously unknown, clinically relevant alterations that are germline, either de novo or inherited from parents, despite a lack of associated clinical history.
Genes sequenced in this panel include:
AKT1 |
CHEK2 |
FGFR3 |
KIT |
NTRK3 |
AKT2 |
CTNNB1 |
FGFR4 |
KRAS |
PDGFRA |
AKT3 |
EGFR |
FLT3 |
MAP2K1 |
PIK3CA |
ALK |
ERBB2 |
GNA11 |
MAP2K2 |
PTEN |
AR |
ERBB3 |
GNAQ |
MET |
RAF1 |
ARAF |
ERBB4 |
GNAS |
MTOR |
RET |
BRAF |
ESR1 |
HRAS |
NRAS |
ROS1 |
CDK4 |
FGFR1 |
IDH1 |
NTRK1 |
SMO |
CDKN2A |
FGFR2 |
IDH2 |
NTRK2 |
TP53 |
Comprehensive Oncomine Precision Assay (OPA) Gene Panel (Thermo Fisher Scientific)
When to Order: Comprehensive Diagnostic Protocol for Solid Tissue Cancers.
How to Order: Fill out our Somatic Mutation testing request form and tick the Somatic Mutation test panels required.
Turnaround Time: 5-7 business days after the receipt of the sample.
Specimen Required: Fresh formalin-fixed paraffin-embedded (FFPE) of 5-10 μm thickness from the tumour tissue.
Test Cost: The Comprehensive Tumour Somatic Mutation Panel is Non-Medicare rebatable. An out-of-pocket fee of $750 applies.
Download Somatic Mutation Request Form Download Somatic Mutation Request Form - WA
The content on our Molecular Cancer Services page is written by Associate Professor Mirette Saad, National Director of Molecular Genetics at Australian Clinical Labs.
 |
Assoc. Prof. Mirette Saad
MBBS (Hons), MD, MAACB, FRCPA, PhD Lab: Clayton Speciality: Chemical Pathology and Molecular Genetics Areas Of Interest: Cancer Genetics, Antenatal Screening, NIPT, Endocrine, Fertility Testing and Research, Medical Teaching Phone: 1300 134 111 Email: mirette.saad@clinicallabs.com.au
|
Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with Microbiology sub-speciality, from Suez Canal University, Egypt. A/P Saad received her NHMRC sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute. Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for non-invasive prenatal testing (NIPT), antenatal screening, personalised drug therapy and cancer.
Back to Molecular Cancer Services Homepage